Exbio — Research products — Antibodies — Other intracellular antigens — Anti-MEK1/2 Purified

Anti-MEK1/2 Purified

Regulatory status

RUO

Antigen

MEK1/2

Clone

PAb (508)

Format

Purified

Reactivity

Human

Application

Variant

0.05 mg

11-508-C050

In stock

132.00 USD

Variant

0.05 mg

11-508-C050

In stock

132.00 USD

Contact distributor

Product details

Description

References

SDS download

Isotype

Rabbit polyclonal

Specificity

The polyclonal antibody reacts with intracellular antigens MEK 1/2. MEK 1 and MEK 2 are integral components of the MAP kinase cascade, an important pathway for cell growth and differentiation.

Application

Application details

Western blotting: Recommended dilution 0.5 μg/ml; positive material: RAJI human Burkitt lymphoma cell line, both reducing and non-reducing conditions, reducing conditions are recommended.

Reactivity

Human

Immunogen

Synthetic peptide (coupled with KLH) derived from aminoacid sequence 33-53 of human MAPK Kinase 1. The immunogen sequence is highly conserved within species (human, mouse, rat, hamster, bovine etc.).

Concentration

1 mg/ml

Preparation

Purified by ligand affinity chromatography.

Formulation

Stabilizing phosphate buffered saline (PBS), pH 7.4, 15 mM sodium azide

Storage and handling

Store at 2-8°C. Do not freeze.

The product is intended For Research Use Only. Diagnostic or therapeutic applications are strictly forbidden. Products shall not be used for resale or transfer to third parties either as a stand-alone product or as a manufacture component of another product without written consent of EXBIO Praha, a.s. EXBIO Praha, a.s. will not be held responsible for patent infringement or any other violations of intellectual property rights that may occur with the use of the products. Orders for all products are accepted subject to the Term and Conditions available at www.exbio.cz. EXBIO, EXBIO Logo, and all other trademarks are property of EXBIO Praha, a.s.

Other names

MAPKK 1/2, MKK1/2

Antigen description

MEK (MAPKK, kinase of mitogen-activated protein kinase) is the medium one of three components of MAP kinase cascade – an important signaling pathway that regulates cell growth and differentiation. Raf (MAPKKK) activates MEK 1 and 2 via phosphorylation of two serine residues (Ser218 and Ser222). Activated MEK 1/2 then acts as a dual specificity kinase phosphorylating both a threonine and a tyrosine residue on ERK (MAPK, mitogen-activated protein kinase). This phosphorylation of ERK by MEK 1/2 is a critical step in the MAP kinase cascade. Phosphorylated ERK is capable of translocating to the nucleus, where it regulates gene expression by activating transcription factors.

General references:

Park ER, Eblen ST, Catling AD: MEK1 activation by PAK: a novel mechanism. Cell Signal. 2007 Jul;19(7):1488-96.
PubMed

Scholl FA, Dumesic PA, Barragan DI, Harada K, Bissonauth V, Charron J, Khavari PA. Mek1/2 MAPK kinases are essential for Mammalian development, homeostasis, and Raf-induced hyperplasia. Dev Cell. 2007 Apr;12(4):615-29.
PubMed

McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M, Tafuri A, Stivala F, Libra M, Basecke J, Evangelisti C, Martelli AM, Franklin RA. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta. 2007 Aug;1773(8):1263-84.
PubMed

Sundaram MV: RTK/Ras/MAPK signaling. WormBook. 2006 Feb 11;:1-19.
PubMed

Park JI, Strock CJ, Ball DW, Nelkin BD: The Ras/Raf/MEK/extracellular signal-regulated kinase pathway induces autocrine-paracrine growth inhibition via the leukemia inhibitory factor/JAK/STAT pathway. Mol Cell Biol. 2003 Jan;23(2):543-54.
PubMed

Chang F, Steelman LS, Lee JT, Shelton JG, Navolanic PM, Blalock WL, Franklin RA, McCubrey JA: Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention. Leukemia. 2003 Jul;17(7):1263-93.
PubMed

Product specific references:

Sikorski K, Mehta A, Inngjerdingen M, Thakor F, Kling S, Kalina T, Nyman TA, Stensland ME, Zhou W, de Souza GA, Holden L, Stuchly J, Templin M, Lund-Johansen F: A high-throughput pipeline for validation of antibodies. Nat Methods. 2018 Nov;15(11):909-912.
PubMed